Cargando…

An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas

BACKGROUND: To evaluate the expression levels of Cyclin D1 in breast papillomas and papillary carcinomas, and to analyze the types of cells that co-express Cyclin D1 with Cytokeratin 5/6 (CK 5/6) or with Cytokeratin 8/18(CK 8/18). METHODS: Fifty-nine cases of papillary lesions including 36 papilloma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Zhu, Jin-fu, Liu, Ying-ying, Han, Gui-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571902/
https://www.ncbi.nlm.nih.gov/pubmed/23327593
http://dx.doi.org/10.1186/1746-1596-8-8
_version_ 1782259230748704768
author Wang, Yu
Zhu, Jin-fu
Liu, Ying-ying
Han, Gui-ping
author_facet Wang, Yu
Zhu, Jin-fu
Liu, Ying-ying
Han, Gui-ping
author_sort Wang, Yu
collection PubMed
description BACKGROUND: To evaluate the expression levels of Cyclin D1 in breast papillomas and papillary carcinomas, and to analyze the types of cells that co-express Cyclin D1 with Cytokeratin 5/6 (CK 5/6) or with Cytokeratin 8/18(CK 8/18). METHODS: Fifty-nine cases of papillary lesions including 36 papillomas and 23 intracystic papillary carcinomas were examined. Cyclin D1, CK 5/6 and CK 8/18 expression levels were evaluated by double immunostaining. RESULTS: Cyclin D1 is highly expressed in papillary carcinomas (27.54% ± 15.43%) compared with papillomas (8.81% ± 8.41%, p < 0.01). Cyclin D1 is predominantly expressed in Cytokeratin 8/18- expressing cells, rather than in Cytokeratin 5/6-expressing cells, regardless of the type of lesion. In Papillomas, Cyclin D1 exhibited a mean 11.42% (11.42% ± 10.17%) co-expression rate with Cytokeratin 8/18 compared with a mean 2.50% (2.50% ± 3.24%) co-expression rate with Cytokeratin 5/6 (p < 0.01). In papillary carcinomas, Cyclin D1 exhibited a mean 34.74% (34.74% ± 16.32%) co-expression rate with Cytokeratin 8/18 compared with a co-expression rate of 0.70% (0.70% ± 0.93%) with Cytokeratin 5/6 (p < 0.01). CONCLUSIONS: The increase in Cyclin D1 suggests an association of Cyclin D1 staining with papillary carcinomas. Although Cyclin D1 is an effective marker for the differential diagnosis of other papillary lesions, it cannot be used to distinguish between papilloma and papillary carcinoma lesions because its expression occurs in both lesions. Our results show that Cyclin D1 and CK 5/6 staining could be used in concert to distinguish between the diagnosis of papilloma (Cyclin D1 < 4.20%, CK 5/6 positive) or papillary carcinoma (Cyclin D1 > 37.00%, CK 5/6 negative). In addition, our data suggest that Cyclin D1 is expressed only in the cancer stem or progenitor cells that co-immunostained with CK 8/18 in papillary carcinomas, and predominantly with CK 8/18 in the papillomas. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7299340558756848
format Online
Article
Text
id pubmed-3571902
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35719022013-02-20 An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas Wang, Yu Zhu, Jin-fu Liu, Ying-ying Han, Gui-ping Diagn Pathol Research BACKGROUND: To evaluate the expression levels of Cyclin D1 in breast papillomas and papillary carcinomas, and to analyze the types of cells that co-express Cyclin D1 with Cytokeratin 5/6 (CK 5/6) or with Cytokeratin 8/18(CK 8/18). METHODS: Fifty-nine cases of papillary lesions including 36 papillomas and 23 intracystic papillary carcinomas were examined. Cyclin D1, CK 5/6 and CK 8/18 expression levels were evaluated by double immunostaining. RESULTS: Cyclin D1 is highly expressed in papillary carcinomas (27.54% ± 15.43%) compared with papillomas (8.81% ± 8.41%, p < 0.01). Cyclin D1 is predominantly expressed in Cytokeratin 8/18- expressing cells, rather than in Cytokeratin 5/6-expressing cells, regardless of the type of lesion. In Papillomas, Cyclin D1 exhibited a mean 11.42% (11.42% ± 10.17%) co-expression rate with Cytokeratin 8/18 compared with a mean 2.50% (2.50% ± 3.24%) co-expression rate with Cytokeratin 5/6 (p < 0.01). In papillary carcinomas, Cyclin D1 exhibited a mean 34.74% (34.74% ± 16.32%) co-expression rate with Cytokeratin 8/18 compared with a co-expression rate of 0.70% (0.70% ± 0.93%) with Cytokeratin 5/6 (p < 0.01). CONCLUSIONS: The increase in Cyclin D1 suggests an association of Cyclin D1 staining with papillary carcinomas. Although Cyclin D1 is an effective marker for the differential diagnosis of other papillary lesions, it cannot be used to distinguish between papilloma and papillary carcinoma lesions because its expression occurs in both lesions. Our results show that Cyclin D1 and CK 5/6 staining could be used in concert to distinguish between the diagnosis of papilloma (Cyclin D1 < 4.20%, CK 5/6 positive) or papillary carcinoma (Cyclin D1 > 37.00%, CK 5/6 negative). In addition, our data suggest that Cyclin D1 is expressed only in the cancer stem or progenitor cells that co-immunostained with CK 8/18 in papillary carcinomas, and predominantly with CK 8/18 in the papillomas. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7299340558756848 BioMed Central 2013-01-18 /pmc/articles/PMC3571902/ /pubmed/23327593 http://dx.doi.org/10.1186/1746-1596-8-8 Text en Copyright ©2013 Wang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wang, Yu
Zhu, Jin-fu
Liu, Ying-ying
Han, Gui-ping
An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title_full An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title_fullStr An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title_full_unstemmed An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title_short An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
title_sort analysis of cyclin d1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571902/
https://www.ncbi.nlm.nih.gov/pubmed/23327593
http://dx.doi.org/10.1186/1746-1596-8-8
work_keys_str_mv AT wangyu ananalysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT zhujinfu ananalysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT liuyingying ananalysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT hanguiping ananalysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT wangyu analysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT zhujinfu analysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT liuyingying analysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas
AT hanguiping analysisofcyclind1cytokeratin56andcytokeratin818expressioninbreastpapillomasandpapillarycarcinomas